FLAMMA once again expands its Continuous Flow capabilities in Italy

The Flamma Group  (“Flamma”) is a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies. Flamma celebrated the Grand Opening of its new state-of-the-art cGMP plant in Dalian, China in June 2025. This milestone aligns with the company’s broader strategy to invest significantly across its global network which included its continued expansion within Italy. Learn more here:

https://www.flammagroup.com/grand-opening-2025/

FLAMMA is a CDMO with Headquarters near Milan, Italy. As a fully integrated CDMO, we can leverage our 100% self-owned, self-managed facilities, in Italy and China to deliver a stable, reliable supply chain. We specialize in the cGMP manufacturing of APIs, NCEs, RSMs, &Advanced intermediates (NCEs and generics). We use our expertise in high value chiral materials (specifically amino acid related materials) to provide solutions to customers who not only have need for chiral materials but also clients who have other requirements with a various type of chemistries. In addition, we also manufacture specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries, and others.

The company wil acquire a third API manufacturing site in Lecco, Italy as of April this year 

Learn about Flamma in under 1 minutes by viewing this video.

We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event.

This one page article describes the tactics being used in the CDMO industry to gain business that ultimately costs innovator companies more money and time.

The CDMO says the suite will help to "bring back manufacturing to the US"

Flamma announced the expansion of its Continuous Flow capabilities with the investment of ~$2M

A short article that features Kenneth Drew, VP Flamma USA discussing what makes Flamma different from other CDMOs.

FLAMMA announced the commitment to invest $200M over the next three years. This significant investment will propel Flamma forward.

Chignolo D’Isola, Bergamo, Italy – June 23, 2025 – The Flamma Group  (“Flamma”) is a global, fully integrated company producing and commercializing small molecule Active Pharmaceutical Ingredients (APIs) for the life science industry. As a preeminent Contract Development and Manufacturing Organization (CDMO) of New Chemical Entities (NCEs) and late stage intermediates for the Innovator Companies, Flamma celebrated the Grand Opening of its new state-of-the-art cGMP plant in Dalian, China. This milestone aligns with the company’s broader strategy to invest significantly across its global network which included its continued expansion within Italy.